MX2019002254A - Anticuerpo bifuncional anti-ctla4 y anti-pd-1, composicion farmaceutica y uso de este. - Google Patents

Anticuerpo bifuncional anti-ctla4 y anti-pd-1, composicion farmaceutica y uso de este.

Info

Publication number
MX2019002254A
MX2019002254A MX2019002254A MX2019002254A MX2019002254A MX 2019002254 A MX2019002254 A MX 2019002254A MX 2019002254 A MX2019002254 A MX 2019002254A MX 2019002254 A MX2019002254 A MX 2019002254A MX 2019002254 A MX2019002254 A MX 2019002254A
Authority
MX
Mexico
Prior art keywords
ctla4
bifunctional antibody
pharmaceutical composition
targets
functional domain
Prior art date
Application number
MX2019002254A
Other languages
English (en)
Inventor
Li Baiyong
Xia Yu
Zhang Peng
Maxwell Wang Zhongmin
Original Assignee
Akeso Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Pharmaceuticals Inc filed Critical Akeso Pharmaceuticals Inc
Publication of MX2019002254A publication Critical patent/MX2019002254A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)

Abstract

Un anticuerpo bifuncional anti-CTLA4 (antígeno asociado al linfocito T citotóxico 4) y anti-PD-1 (muerte celular programada 1), una composición farmacéutica del mismo y el uso del mismo. Particularmente, el anticuerpo bifuncional anti-CLTA4 y anti-PD-1 comprende un primer dominio funcional de proteína que se dirige a PD-1 y un segundo dominio funcional de proteína que se dirige a CTLA-4. El anticuerpo bifuncional puede unirse específicamente a CTLA-4 y PD-1, aliviar la inmunosupresión de CTLA4 y PD-1 en un organismo específicamente, activar los linfocitos T, y, por lo tanto, tiene buenas perspectivas de aplicación.
MX2019002254A 2016-08-23 2017-08-22 Anticuerpo bifuncional anti-ctla4 y anti-pd-1, composicion farmaceutica y uso de este. MX2019002254A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610705624.2A CN106967172B (zh) 2016-08-23 2016-08-23 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
PCT/CN2017/098466 WO2018036473A1 (zh) 2016-08-23 2017-08-22 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途

Publications (1)

Publication Number Publication Date
MX2019002254A true MX2019002254A (es) 2019-11-28

Family

ID=59334390

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002254A MX2019002254A (es) 2016-08-23 2017-08-22 Anticuerpo bifuncional anti-ctla4 y anti-pd-1, composicion farmaceutica y uso de este.

Country Status (14)

Country Link
US (2) US11578128B2 (es)
EP (1) EP3511346A4 (es)
JP (2) JP7425604B2 (es)
KR (1) KR102503084B1 (es)
CN (1) CN106967172B (es)
AU (1) AU2017317124A1 (es)
BR (1) BR112019003695A2 (es)
CA (1) CA3034850A1 (es)
EA (1) EA201990571A1 (es)
IL (1) IL264964B2 (es)
MX (1) MX2019002254A (es)
NZ (1) NZ751904A (es)
SG (1) SG11201901583WA (es)
WO (1) WO2018036473A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016294440B2 (en) 2015-07-13 2022-10-13 Cytomx Therapeutics, Inc Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof
RU2767357C2 (ru) 2016-06-14 2022-03-17 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
CN106977602B (zh) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN108866635B (zh) * 2017-05-09 2021-11-26 安升（上海）医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用
JP7145895B2 (ja) 2017-09-01 2022-10-03 四川科倫博泰生物医薬股▲フン▼有限公司 組換え二重特異性抗体
EP3703736A4 (en) * 2017-11-02 2021-11-03 Systimmune, Inc. BISPECIFIC ANTIBODIES AND RELATED MANUFACTURING AND USE PROCESSES
WO2019179421A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
CN110407942B (zh) * 2018-04-27 2022-02-22 苏州康宁杰瑞生物科技有限公司 针对kn044的单域抗体
TWI831789B (zh) 2018-06-05 2024-02-11 大陸商江蘇康寧杰瑞生物製藥有限公司 二聚體及其用途
CN110684113A (zh) * 2018-07-06 2020-01-14 复旦大学 一种抗PD-1抗原和抗c-Met抗原的双特异性抗体及其构建方法
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
WO2020057611A1 (en) * 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific ctla-4/pd-1 polypeptide complexes
WO2020057610A1 (en) * 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
CN111763261B (zh) * 2019-04-02 2022-08-09 杭州尚健生物技术有限公司 一种融合蛋白及其用途
CN112175087B (zh) * 2019-07-02 2022-05-13 深圳市迈加瑞生物技术有限公司 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
EP3998286A4 (en) * 2019-07-11 2023-04-26 Wuhan Yzy Biopharma Co., Ltd. QUAD VALUE SYMMETRIC BISPECIFIC ANTIBODIES
CA3146777A1 (en) 2019-08-02 2021-02-11 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-pd-1 antibody and pharmaceutical use thereof
EP4008730A4 (en) * 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
CN110563845A (zh) * 2019-09-12 2019-12-13 滨州医学院 抗igsf9抗体、药物组合物及其应用
CN112830972A (zh) 2019-11-25 2021-05-25 中山康方生物医药有限公司 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途
EP4069746A4 (en) * 2019-12-04 2023-12-27 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. BISPECIFIC FUSION PROTEIN FOR TUMOR TREATMENT
JP2023522730A (ja) * 2020-04-22 2023-05-31 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用
WO2021213523A1 (zh) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
CN113577255B (zh) * 2020-04-30 2023-09-08 中国科学院上海药物研究所 肿瘤纳米疫苗、其制备方法及用途
CN111944760A (zh) * 2020-08-14 2020-11-17 广东先康达生物科技有限公司 一种分泌双特异性抗体的免疫细胞及其应用
CN112079926A (zh) * 2020-09-17 2020-12-15 北京华大蛋白质研发中心有限公司 抗人ctla4单克隆抗体及其应用
AU2021363350A1 (en) * 2020-10-23 2023-06-22 Akeso Biopharma, Inc Anti-cd73 antibody and use thereof
WO2022188867A1 (zh) * 2021-03-12 2022-09-15 中山康方生物医药有限公司 提高含有免疫球蛋白Fc片段的药物的安全性的方法
AU2022233411A1 (en) 2021-03-12 2023-09-14 Akeso Biopharma, Inc. Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
BR112023021177A2 (pt) 2021-04-14 2023-12-19 Ad Pharmaceuticals Co Ltd Anticorpo, composição farmacêutica, uso do anticorpo, método para prevenir e/ou tratar um tumor, kit, formulação unitária, método para prevenir ou tratar um câncer ou tumor e unidade de dose única
CN113501879B (zh) * 2021-06-30 2022-09-06 拜盖特生物科技(上海)有限公司 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
CA3233205A1 (en) 2021-09-29 2023-04-06 Yu Xia Anti-lag3 antibody, pharmaceutical composition and use
WO2023143597A1 (en) * 2022-01-30 2023-08-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ctla4/ox40 bispecific antibodies and uses thereof
WO2024051223A1 (zh) 2022-09-09 2024-03-14 中山康方生物医药有限公司 药物组合及用途
CN116396392B (zh) * 2023-01-17 2023-10-27 珠海重链生物科技有限公司 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
MXPA05006828A (es) 2002-12-23 2005-09-08 Wyeth Corp Anticuerpos contra pd-1, y sus usos.
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
TW201134481A (en) * 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
KR102031020B1 (ko) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
WO2014022758A1 (en) 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
PT3081576T (pt) * 2013-12-12 2019-10-15 Jiangsu Hengrui Medicine Co Anticorpo pd-1, fragmento de ligação ao antigénio do mesmo e aplicação médica do mesmo
MX2016008189A (es) 2014-01-03 2016-09-29 Hoffmann La Roche Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CN104974253A (zh) 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CN104987421A (zh) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
CN105175545B (zh) 2015-10-20 2019-01-25 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd-1双功能抗体及其应用
CN105175544B (zh) * 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
CN105754990A (zh) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途

Also Published As

Publication number Publication date
KR20190052677A (ko) 2019-05-16
US20190185569A1 (en) 2019-06-20
IL264964B1 (en) 2023-06-01
SG11201901583WA (en) 2019-03-28
BR112019003695A2 (pt) 2019-06-04
US11578128B2 (en) 2023-02-14
CN106967172A (zh) 2017-07-21
EP3511346A1 (en) 2019-07-17
IL264964A (es) 2019-04-30
JP2019533475A (ja) 2019-11-21
CN106967172B (zh) 2019-01-08
US20240010728A1 (en) 2024-01-11
EA201990571A1 (ru) 2019-08-30
JP7425604B2 (ja) 2024-01-31
WO2018036473A1 (zh) 2018-03-01
CA3034850A1 (en) 2018-03-01
EP3511346A4 (en) 2020-04-29
JP2022130393A (ja) 2022-09-06
IL264964B2 (en) 2023-10-01
AU2017317124A1 (en) 2019-04-11
KR102503084B1 (ko) 2023-02-24
NZ751904A (en) 2023-01-27

Similar Documents

Publication Publication Date Title
NZ751904A (en) Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof
NZ734256A (en) Use of plinabulin in combination with immune checkpoint inhibitors
CY1124190T1 (el) Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση
MX2022006447A (es) Anticuerpos anti-pd-1 novedosos.
EA202190535A1 (ru) Бифункциональное антитело против pd-1 и против vegfa, его фармацевтическая композиция и его применение
ZA201901781B (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
ECSP19040905A (es) Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1
SG11201906780SA (en) Bcma-targeting antibody and use thereof
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
HRP20221284T1 (hr) Anti-pvrig antitijela i postupci uporabe
PH12021551439A1 (en) Irreversible inhibitors of menin-mll interaction
WO2018075820A3 (en) Cereblon-based heterodimerizable chimeric antigen receptors
MX2021007274A (es) Molecula bifuncional anti-pd-1/sirpa.
MX2020000055A (es) Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
MX2021005236A (es) Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.
EP3768719A4 (en) HIGH AFFINITY NEUTRALIZING ANTIBODIES AGAINST PROGRAMMED DEATH LIGAND 1 (PD-L1) AND THEIR USE
WO2019152356A3 (en) Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies
MX2020009864A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1.
MX2021005686A (es) Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer.
MX2021007369A (es) Combinacion farmaceutica de anticuerpos anti ceacam6 y tim3.
WO2021113307A3 (en) Antibodies against pd-l1 and methods of use thereof
MX2023002705A (es) Combinaciones de lurbinectedina e inhibidor en el punto de control inmunitario.